It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Shionogi Grabs Rights to Rohto’s Cell-Based Hepatic Cirrhosis Therapy
September 14, 2018
- Poxel Forms Japan Outpost, Hitches Janssen’s Kaneko as Country Chief
September 14, 2018
- I/O in Lung Cancer - 5: Roche Looks Beyond Tecentriq, Laying Foundation for Next-Gen Immunotherapies
September 13, 2018
- Ex-AZ Exec Nogami Tapped to Lead Takeda Consumer Healthcare
September 13, 2018
- Kowa Continues Heavy GP Pitch for Parmodia in July: Anterio
September 13, 2018
- Nippon Shinyaku Eyes Conditional Early OK for Sakigake DMD Drug, Daiichi Sankyo Redoing PI/II for Its Antisense
September 12, 2018
- Quizartinib Earns Japan Orphan Status for AML: Daiichi Sankyo
September 12, 2018
- Avastin Best-Selling Drug in Japan in August: Encise Snapshot
September 12, 2018
- Risankizumab Hits Primary Endpoint in Japan PII/III Study with Psoriasis Vulgaris Patients: AbbVie
September 11, 2018
- Power Back On at Drug Makers’ Hokkaido Plants
September 11, 2018
- Tremfya Meets Primary Endpoint in Japan PIII Study for Palmoplantar Pustulosis: Janssen
September 11, 2018
- Ethical Drug Sales Up 3.6% in July: Crecon
September 11, 2018
- Shionogi Loses HIV Patent Battle against MSD
September 10, 2018
- Hokkaido Quake Hits Wholesaler Price Negotiations as Sept. Deadline for Medical Fee Cuts Looms
September 10, 2018
- Sanofi to Focus on Increasing Prescriptions of Lantus XR Based on Results of Head-to-Head Comparison Study
September 10, 2018
- Xofluza Cuts Flu Symptoms, Vial Loads: Shionogi
September 7, 2018
- Ono to Divide Oncology Sales Force into Two Units as Opdivo Label Expands
September 7, 2018
- Giant Quake Disrupts Drug Production, Shipments in Hokkaido; Distributors Scramble to Ensure Supplies
September 7, 2018
- Huahai Already Developed New Manufacturing Process for Valsartan API, Says Japan Chief after JMA Criticism on Impurity Issue
September 6, 2018
- Sawai’s Abilify Generic Approved for Bipolar Disorder
September 6, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…